CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquires HemaCare Corporation
Snapshot
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired HemaCare Corporation for $379.8 million in cash in January 2020. The transaction was structured as all cash. HemaCare Corporation is a United States (Los Angeles, California)-based Manufacturing Support — Biologics / cell therapy business.
- Acquirer
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- Target
- HemaCare Corporation
- Value
- $379.8 million in cash
- Date
- January 2020
- Type
- full acquisition
- Status
- ready
The deal at a glance
About this deal
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired HemaCare Corporation for $379.8 million in cash, a transaction completed in January 2020, structured as all cash.
HemaCare Corporation operates in Manufacturing Support — Biologics / cell therapy, is based in United States (Los Angeles, California). HemaCare Corporation was a business specializing in the production of human-derived cellular products for the cell therapy market.
The acquisition of HemaCare expands our comprehensive portfolio of early-stage research and manufacturing support solutions to encompass the production and customization of high-quality, human-derived cellular products to better support clients' cell therapy programs. The purchase price of HemaCare was $379.8 million in cash.
Manufacturing Support segment, cell therapy
No advisory firms have been disclosed for this transaction.